Localization | 2009.11.20
European CHMP Formally Adopts Negative Opinion on Oncophage®
LONDON--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). A negative vote of the CHMP indicating this opinion was verbally conveyed to Antigenics and announced i
For more information, please visit
http://www.businesswire.com/news/home/20091120005306/en
